Uncategorized
InSite releases positive results for phase 3 trial of BromSite
InSite Vision announced top-line results from its confirmatory phase 3 clinical trial of BromSite for the reduction of inflammation and pain after cataract surgery, according to a press release. The study included 248 patients who underwent cataract surgery in a two-arm trial to evaluate the efficacy and safety of BromSite (bromfenac 0.075% with DuraSite drug delivery technology) against the DuraSite vehicle alone. Patients were randomized and dosed twice a day 1 day before surgery, the day of surgery and 14 days after surgery.